We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.025 | -2.94% | 0.825 | 0.80 | 0.85 | 0.85 | 0.7925 | 0.85 | 823,510 | 16:06:06 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.44 | 1.48M |
From Apr 2019 to Apr 2024
TIDMN4P
RNS Number : 8771I
N4 Pharma PLC
13 August 2019
13 August 2019
N4 Pharma Plc
("N4 Pharma" or the "Company")
Holdings in Company
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for vaccines and cancer treatments, announces that it has been notified that, following a purchase of 112,258 ordinary shares of 0.4p each in the company ("Ordinary Shares") earlier today, Mr David Farrier is now beneficially interested in 12,175,510 Ordinary Shares, representing 12.0 per cent. of the Company's issued share capital.
Enquiries:
N4 Pharma Plc Via Scott PR Nigel Theobald, CEO Allenby Capital Limited Tel: +44(0)203 328 5656 James Reeve/Asha Chotai Scott PR Tel: +44(0)1477 539 539 Georgia Smith
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
HOLLLFLITSIVLIA
(END) Dow Jones Newswires
August 13, 2019 06:16 ET (10:16 GMT)
1 Year N4 Pharma Chart |
1 Month N4 Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
